Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
142.50    -1.00 (-0.70%)
Bid:
142.00
Ask:
143.00
Spread: 1.00 (0.704%)
Market Cap: £120.60m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Investor Presentation

21 Feb 2022 07:00

RNS Number : 1842C
Diaceutics PLC
21 February 2022
 

21 February 2022

Diaceutics PLC

("Diaceutics" or the "Group" or the "Company")

Investor Presentation

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that CEO Peter Keeling and incoming CFO Nick Roberts will provide a live presentation relating to the Company's audited results for the year ended 31 December 2021 via the Investor Meet Company platform on 23 March 2022 at 1pm.

 

The presentation is open to all existing and potential shareholders and registration can be completed via the following link:

 

https://www.investormeetcompany.com/diaceutics-plc/register-investor.

 

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

 

Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.

 

Enquiries:

Diaceutics PLC 

Peter Keeling, Chief Executive Officer

 

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison

Stewart Wallace

Nick Adams

 

Alma PR

Caroline Forde

Kieran Breheny

Matthew Young

 Via Alma PR

 

Tel: +44 (0)20 7710 7600

 

 

Tel: +44(0)20 3405 0205

diaceutics@almapr.co.uk

 

 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAQVLFFLLLFBBL
Date   Source Headline
1st Sep 20217:00 amRNSPDMR Shareholding/Share Incentive Plan
31st Aug 20217:00 amRNSNotice of Investor Presentation
30th Jul 20214:54 pmRNSPDMR Shareholding/Share Incentive Plan
8th Jul 20217:00 amRNSTrading Update
1st Jul 20217:00 amRNSIssue of Share Options and PDMR Shareholdings
29th Jun 20214:56 pmRNSPDMR Shareholding/Share Incentive Plan
24th Jun 20217:00 amRNSNew Contract Wins
18th Jun 20217:00 amRNSPurchase of Shares and PDMR Shareholding
16th Jun 20217:00 amRNSCapital Markets Day and KPI Update
7th Jun 20216:23 pmRNSPDMR Shareholding/Share Incentive Plan
7th Jun 20217:00 amRNSNotice of Capital Markets Day
4th Jun 20217:00 amRNSPresenting data on COVID impact on cancer at ASCO
21st May 20211:49 pmRNSHolding(s) in Company
21st May 20217:00 amRNSChange of Adviser
19th May 20213:24 pmRNSResult of AGM
13th May 20217:00 amRNSLGC SeraCare Partnership
12th May 20215:58 pmRNSSale of Shares and PDMR Shareholding
5th May 20216:03 pmRNSHolding(s) in Company
4th May 20213:11 pmRNSSale of Shares and Director/PDMR Shareholding
30th Apr 202111:01 amRNSShare Incentive Plan
21st Apr 20217:00 amRNSNotice of AGM and posting of Annual Report
12th Apr 20217:00 amRNSNew Vice President of Operations in Asia
8th Apr 20219:49 amRNSTransfer of Shares and Director/PDMR Shareholding
7th Apr 20217:58 amRNSTransfer of Shares and Director/PDMR Shareholding
6th Apr 202111:12 amRNSIssue of Share Options/PDMR Shareholdings
1st Apr 20217:00 amRNSCOVID-19 Testing Data licensing agreement
30th Mar 20217:00 amRNSNew lease agreement and related party transaction
15th Mar 20217:00 amRNSFinal Results
8th Mar 20217:00 amRNSNotice of Results
4th Mar 202112:49 pmRNSNew Vice President of Finance appointment
21st Jan 20217:00 amRNSQuarterly media update
11th Jan 20219:56 amRNSHolding(s) in Company
11th Jan 20217:00 amRNSTrading update
22nd Dec 20207:01 amRNSDirectorate Change
22nd Dec 20207:00 amRNSDirectorate Change
10th Dec 20203:10 pmRNSHolding(s) in Company
17th Nov 20207:00 amRNSEuropean international award win
10th Nov 20204:32 pmRNSHolding(s) in Company
28th Oct 20207:00 amRNSCommercial launch of DXRX
7th Sep 20202:05 pmRNSSecond Price Monitoring Extn
7th Sep 20202:00 pmRNSPrice Monitoring Extension
7th Sep 202011:00 amRNSPrice Monitoring Extension
7th Sep 20207:00 amRNSHalf-year Report
27th Aug 20207:00 amRNSNotice of Results
22nd Jul 20207:00 amRNSNew contract win for DXRX platform
9th Jul 20207:00 amRNSHolding(s) in Company
8th Jul 20207:00 amRNSTrading update
6th Jul 20204:41 pmRNSSecond Price Monitoring Extn
6th Jul 20204:36 pmRNSPrice Monitoring Extension
3rd Jul 202010:43 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.